Drug Profile
ITK 1
Alternative Names: Personalised peptide vaccineLatest Information Update: 22 Aug 2019
Price :
$50
*
At a glance
- Originator Kurume University
- Developer BrightPath Biotherapeutics; FUJIFILM Corporation; Kurume University
- Class Cancer vaccines; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glioblastoma; Prostate cancer
Most Recent Events
- 22 Aug 2019 Discontinued - Phase-III for Glioblastoma (Monotherapy, Second-line therapy or greater) in Japan (SC)
- 22 Aug 2019 Discontinued - Phase-III for Prostate cancer (Hormone refractory, Second-line therapy or greater) in Japan (SC)
- 31 Mar 2018 FUJIFILM Corporation completes a phase III trial in Prostate cancer (hormone-refractory; second-line therapy or greater) in Japan (SC) (UMIN000011308)